

Effects of moderate whole-body hyperthermia and complementary medicine in the treatment of rheumatoid arthritis: a preliminary study

Siddarth Agrawal

Integrative Medical Center Sp. z o. o.
Poland

Presented at 35th ICMS, Guangzhou, 2017

Cite this article as:

Agrawal S. (2018): Effects of moderate whole-body hyperthermia and complementary medicine in the treatment of rheumatoid arthritis: a preliminary study; *Oncothermia Journal* 22:8-19

www.oncothermia-journal.com/journal/2018/Effects_of_moderate_whole_body.pdf

Effects of moderate whole-body hyperthermia and complementary medicine in the treatment of rheumatoid arthritis: a preliminary study

Abstract

It is estimated that more than two-thirds of patients with rheumatoid arthritis (RA) use complementary and alternative medicine (CAM). The rationale for the use of some CAM therapies is supported by reasonable evidence. 8 patients with RA were included in the preliminary study. Patients received treatment that included whole-body hyperthermia, ozone major autohemotherapy, intravenous vitamin C and individual nutrition counselling for 4 weeks. The patient's perceptions of pain, stiffness, and fatigue were measured on a 100-mm visual analogue scale and were considered as primary outcomes. In all patients, a significant improvement was seen at the end of the treatment and post-treatment. Pain and stiffness reduced over 40%, while fatigue nearly 60% for patients with RA. More importantly, the treatment was found to be safe and did not relate with any adverse events. The results of this study are encouraging and may become a platform for future planning of long-term studies with the complementary treatments in combination with existing standard therapies in RA.

Introduction

Rheumatoid arthritis (RA) is a symmetric, inflammatory, peripheral polyarthritis of unknown aetiology, which affects multiple small joints of the hands and feet. The evolution of hyperplastic synovial tissue, leads to deformity through the stretching of tendons and ligaments and destruction of joints through the erosion of cartilage and bone.

It is estimated that 60% to 90% of persons with arthritis, particularly those with rheumatoid arthritis, have used complementary and alternative medicine (CAM) [1]. The rationale for the use of some therapies is supported by a reasonable and fairly consistent body of evidence.

Heat treatment in patients with rheumatic disorders has been used through the ages. Initially, the application of hyperthermia treatment was mainly empirical. In the last few decades evidence from clinical studies documented its beneficial effects in RA [2,3]. Pain and stiffness decrease, and grip strength and range of motion improve after application of local hyperthermia [4]. Some studies reported beneficial effects of whole-body hyperthermia (WBH) [5,6].

In this preliminary study, the effectiveness of whole-body hyperthermia and complementary therapies in the treatment of rheumatoid arthritis was evaluated.

Material and methods

8 patients with RA were included in the study. Patients received treatment for 4 weeks. After oral and written information about the treatment and the possible clinical effects of applied therapies, patients were invited to the study. Informed consent was obtained from all patients. Clinical measurements were performed before the start of the treatment, at the end of the 4-week period of therapy and one month after the end of the treatment series. The patient's perceptions of pain [7], stiffness [8], and fatigue [9–11] were measured on a 100-mm visual analogue scale and were considered as primary outcomes.

Statistical analysis

The conformity assessment was carried out by the Shapiro-Wilk test. The homogeneity of variance was tested with Bartlett's test. The significance of differences in mean values (M) in more than two populations for parameters of normal distribution and of homogeneous variances was assessed with analysis of variance (ANOVA). In case of rejection of the null hypothesis of homogeneity of variance, to verify the differences between the mean values in pairs, post-hoc tests were performed (Scheffe test). The level $p = 0.05$ was assumed as the critical significance level. Data was expressed as $M \pm SD$ and analysed with the statistical program STATISTICA v.12 (StatSoft, Inc. Tulsa, USA).

Treatment protocol

The treatment protocol consisted of: 4 moderate whole-body hyperthermia sessions (once every week), 8 sessions (twice every week) of ozone major autohemotherapy (MAHT) and intravenous vitamin C (IVC), as well as two individual nutrition counselling.

Results

Patient characteristics. A total of 8 patients (6 female, 2 male) with RA were included in the study with mean age of 51 (Table 1). One patient dropped out in the treatment period due to nonmedical reasons and could not be measured for follow-up. Hence, the mean group results of 7 patients are presented in Table 2. Pain and stiffness ($p < 0.05$) as well as fatigue ($p < 0.001$) significantly decreased at the end of the treatment and post-treatment periods.

Discussion

In all patients, a clinically significant improvement was seen at the end of the treatment and post-treatment. Pain and stiffness reduced over 40%, while fatigue nearly 60% for patients with RA (Table 2). The effect of whole-body hyperthermia upon local joint inflammation or disease activity is not clear. The findings of earlier studies were ambiguous [12-18], and many studies have no optimal quality as summarized in the COCHRANE study [2]. It is known that whole-body hyperthermia can enhance immune surveillance, including increased mobility and activity of white blood cells [19,20]. It is hypothesized that increased temperature can modulate the immune response by targeting the intracellular signalling pathways, cytokines, and other mediators of the phases of RA.

Ozone major autohemotherapy was first described in 1954 [21] and since then, after Wolff's modification [22], it has been carried out worldwide millions of times without side-effects and with therapeutic results [23]. The rationale for the use of ozone is based on its immunosuppressive action if it is used at high concentration (45-65 $\mu\text{g}/\text{ml}$) [24]. Several studies described its anti-inflammatory and analgesic effects [25,26], the functional recovery of muscle and joint groups [27,28], as well as perfusion improvement of

microcirculation [29]. A study by Chang et al. demonstrated that ozone applied externally ameliorated the inflammatory reaction of RA without toxicity or serious side effects [30]. The authors found that the decrease in cytokine synthesis and secretion was due to the pouring of ozone into the inflamed and infiltrated area via oxidation and eliminating the hyperplastic synovial fibroblasts. Our study showed that ozone in the form of MAHT was well-tolerated and contributed to the beneficial outcome of the therapy.

Oxidative stress and severe systemic inflammation have been considered as important pathophysiologic mechanisms involved in the development of RA [31, 32]. Oxidative stress occurs in response to the oxidative damage resulting from imbalance between antioxidant and scavenging ability and the active oxidants produced by a harmful stimulant [32, 33]. Previous reports showed that significantly elevated production of reactive oxygen species (ROS) in the serum of RA patients can be observed comparing with healthy donors [34]. ROS are indirectly involved in joint damage as the secondary messengers in inflammatory and immunological cellular response in RA, which also can degrade directly the joint cartilage, influencing its proteoglycan and inhibiting its synthesis [35, 36].

In this study, the rationale for the use of IVC and diet modification has been based on their anti-inflammatory action. Vitamin C has direct antioxidant capacity and contributes to the protection of cells from the damaging effects of endogenously produced or exogenous reactive oxygen radicals and reactive nitrogen species, e.g. during immune activation. Vitamin C prevents oxidative damage to lipids, proteins, and DNA, which has been implicated as a major contributing factor in the development of chronic diseases such as cardiovascular disease, cancer, and cataract, respectively [37,38]. Evidence further suggests that vitamin C provides indirect antioxidant protection by regenerating other biologically important antioxidants such as glutathione and vitamin E to their active state [39]. The nutritional and physiological aspects of this essential nutrient have been widely reviewed in a large number of comprehensive publications on vitamin C [37,40]. To our knowledge, this is the first study that evaluated the demonstrated that IVC is safe and does not correlate with any adverse events.

Among a number of small clinical trials of dietary manipulation in RA, modest benefit has been noted for high-dose omega-3 fatty acids, fasting, vegetarian diet, and Mediterranean-type diet [41-43]. In a recent study by Tedeschi et al. [44] 24.0% of subjects in a prospective,

longitudinal RA registry reported that foods affect their RA symptoms, and 24.3% avoid foods due to worsening of their RA. Among a list of 20 specific foods, blueberries and spinach were most often noted to improve RA, while soda with sugar and desserts were most commonly reported to worsen RA. Past work has shown that greater consumption of sugar-sweetened beverages is associated with increased risk for developing RA [45].

In this study, a certified nutritionist provided face-to-face counselling that was individually tailored to each patient. Each counselling session lasted 30 to 60 minutes, during which nutritionists educated and strongly recommended patients to follow an anti-inflammatory diet. The Western-type diet, which is high in red meat, high-fat dairy products, refined grains, and simple carbohydrates, has been associated with higher levels of CRP and IL-6 [46]. On the other hand, the anti-inflammatory Mediterranean diet, which is high in whole grains, fish, fruit and green vegetables, and associated with moderate alcohol and olive oil intake and low intake of red meat and butter has been associated with lower levels of inflammation [47–51]. Diets high in fruit and vegetable intake have been associated with lower levels of CRP [52–54]. Specific nutrients such as (n-3) fatty acids [55–56], fiber [57–58], moderate alcohol intake [59–60], vitamin C [61–62], β -carotene [63–64], and magnesium [65–66] have also consistently been shown to be associated with lower levels of inflammation. In our study, we observed that individual counselling can greatly affect engagement and compliance to the prescribed diet. Post-treatment all patients reported that they follow the dietary guidelines.

In conclusion, WBH and complementary therapies were safe and well-tolerated when given up to 4 weeks. Although our present data are limited in terms of small sample size and lack of control group they are encouraging and may become a platform for future planning of long-term studies with the complementary treatments in combination with existing standard therapies in RA. The multifaceted approach presented in this research consisted of immunomodulating heat therapy in the form of WBH, immunosuppressive and regenerative therapy in the form of MAHT and anti-inflammatory IVC and nutritional counselling. While we cannot draw strong conclusions based on this study, the suggested multimodal approach may be beneficial in the management of refractory RA.

Tables

Table 1

Gender	2 males, 6 females
Age	51 yrs. [SD=11.21; range=33-63]
Disease duration	8.2 yrs. [SD=6.36; range=1-17]

Table 2

	Before treatment	End of treatment	Post-treatment
Pain	44 (4)	24 (5)*	25 (5)*
Stiffness	38 (6)	21 (3)*	23 (4)*
Fatigue	41 (7)	17 (3)**	18 (4)**

VAS, 0–100 mm; mean (SD), *p<0.05; ** p<0.01 vs. before treatment

References

1. Rao, Jaya K., et al. Use of complementary therapies for arthritis among patients of rheumatologists. *Annals of internal medicine* 1999; 409-416.
2. Robinson VA, Brosseau L, Casimiro L, Judd MG, Shea BJ, Tugwell P, Wells G. Thermotherapy for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2002, Issue 2. Art. No.: D002826.DOI:10.1002/14651858.CD002826.
3. French SD, Cameron M, Walker BF, Reggars JW, Esterman AJ. Superficial heat or cold for low back pain. *Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD004750. DOI: 10.1002/14651858.CD004750.pub2.
4. Oosterveld FGJ, Rasker JJ. Treating Arthritis With Locally Applied Heat or Cold. *Semin Arthritis Rheum* 1994;24:82-90.
5. Sukenik S, Abu-Shakra M, Flusser D. Balneotherapy in autoimmune disease. *Isr J Med Sci* 1997;33:258-61.
6. Verhagen AP, Bierma-Zeinstra SMA, Cardoso JR, de Bie RA, Boers M, de Vet HCW.

Balneotherapy for rheumatoid arthritis Cochrane Database of Systematic Reviews 2004 Issue 1. Art. No:CD000518.DOI:10.1002/14651858.CD000518.

7. Melzack R, Katz J (1994) Pain measurement in persons in pain. In: Wall PD, Melzack R (eds) Textbook of pain. 3rd edn. Churchill Livingstone, Edinburgh, pp 337–351

8. Oosterhof J (1992) The reliability of Visual Analogue Scale measurements for stiffness in patients with rheumatoid arthritis. NPI, Amersfoort

9. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JMGW, Wiegman O (1998) Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. *Br J Rheumatol* 37:1042–1046

10. van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, van der Linden S, van der Heijde D (2002) Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. *Arthritis Rheum* 47(1):8–16 Feb

11. Jones SD, Koh WH, Steiner A, Garrett SL, Calin A (1996) Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. *J Rheumatol* 23:487–490

12. Licht S (1982) Physical therapy in arthritis. In: Lehman JF (ed) Therapeutic heat and cold. 3rd edn. Williams & Wilkins, Baltimore, pp 263–269

13. Kirk JA, Kersley GD (1968) Heat and cold in the physical treatment of rheumatoid arthritis of the knee. *Ann Phys Med* 9:270–274

14. Mainardi CL, Walter JM, Spiegel PK, Goldkamp OG, Harris ED (1979) Rheumatoid arthritis: failure of daily heat therapy to affect its progression. *Arch Phys Med Rehabil* 60:390–393

15. Schmidt KL, Mäurer R, Rusch D (1980) Zum Verhalten der Hauttemperatur über entzündeten Kniegelenken unter täglicher Kryotherapie. *Z Phys Med* 9:58–59

16. Zivkovic M, Cvetkovic S, Jovic D (1986) Effects of thermotherapy on acute phase reactants in rheumatoid arthritis and ankylosing spondylitis. *Arthritis Rheum* 29:57 (suppl)

17. Schmidt KL, Ott VR, Rocher G, Schaller H (1979) Heat, cold and inflammation (a review). *Z Rheumatol* 38:391–404

18. Oosterveld FGJ, Rasker JJ (1994) Treating arthritis with locally applied heat or cold. *Semin Arthritis Rheum* 24:82–90

19. Nahas GG, Tannieres ML, Lennon JF. Direct measurement of leukocyte motility: effects of pH and temperature. *Proc Soc Exp Biol Med*. 1971; 138: 350±52.

20. Moore TC, Nur K, Storm FK. Localized deep hyperthermia increases the traffic of lymphocytes through peripheral lymph nodes of sheep in vivo. *J Surg Oncol* 1987; 35:75±81.

21. Wehrli F, Steinbart H. Erfahrungen mit der hamatogen oxidation therapie (hot) *Ars Medici*. 1954;10:44–51.
22. Wolff HH. Die Behandlung peripherer Durchblutungsstörungen mit Ozon. *Erfahr Hk*. 1971;23:181–184.
23. Bocci, V. (2013). *Oxygen-ozone therapy: a critical evaluation*. Springer Science & Business Media.
24. Plopper CG, Duan X, Buckpitt AR, Pinkerton KE. Dose-dependent tolerance to ozone. IV. Site-specific elevation in antioxidant enzymes in the lungs of rats exposed for 90 days or 20 months. *Toxicol Appl Pharmacol* 1994;127(1):124-31.
25. Christian DL, Chen LL, Scannell CH, Ferrando RE, Welch BS, Balmes JR. Ozone-induced inflammation is attenuated with multiday exposure. *Am J Respir Crit Care Med* 1998;158:532–537
26. Clavo B, Perez JL, Lopez L, Suarez G, Lloret M, Rodriguez V, et al. Effect of ozone therapy on muscle oxygenation. *J Altern Complement Med* 2003;9:251–6
27. Sroczyński J, Antoszewski Z, Rudzki H, Matyszczyk B, Kuźniewicz R. Various parameters of lipid metabolism after intra-arterial injections of ozone in patients with ischemia of the lower extremities and diabetes mellitus. *Pol Tyg Lek*1990; 45(47-48):953-5.
28. Rovira G, Ralindo N. La ozonoterapia en el tratamiento de las ulceras cronicas de las extremidades inferiores. *Angiologia* 1991;2:47-50
29. Peralta C, Leon OS, Xaus C, Prats N, Jalil EC, Planell ES, et al. Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance. *Free Radic Res* 1999; 31:191–6
30. Chang, J.D.S., Lu, HS., Chang, YF. et al. *Rheumatol Int* (2005) 26: 142.
31. Meng J, Yu P, Jiang H, Yuan T, Liu N, Tong J, Chen H, Bao N and Zhao J. Molecular hydrogen decelerates rheumatoid arthritis progression through inhibition of oxidative stress. *Am J Transl Res* 2016; 8: 4472-4477.
32. Matyska-Piekarska E, Luszczewski A, Lacki J and Wawer I. The role of oxidative stress in the etiopathogenesis of rheumatoid arthritis]. *Postepy Hig Med Dosw (Online)* 2006; 60: 617- 623.
33. Filippin LI, Vercelino R, Marroni NP and Xavier RM. Redox signalling and the inflammatory response in rheumatoid arthritis. *Clin Exp Immunol* 2008; 152: 415-422.

34. Mateen S, Moin S, Khan AQ, Zafar A and Fatima N. Increased reactive oxygen species formation and oxidative stress in rheumatoid arthritis. *PLoS One* 2016; 11: e0152925.
35. Mirshafiey A and Mohsenzadegan M. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. *Iran J Allergy Asthma Immunol* 2008; 7: 195-202.
36. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. *Panminerva Med* 2003; 45: 7-13.
37. Dietary Reference Intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the Panel on Antioxidants and Related compounds, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes; Food and Nutrition Board, Institute of Medicine. Washington, National Academy Press, 2000, chapter 5: Vitamin C, pp 95–185.
38. Carr AC, Frei B: Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am J Clin Nutr* 1999; 69: 1086–1107.
39. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci USA* 1993; 90: 7915–7922.
40. Jacob RA: The integrated antioxidant system. *Nutr Res* 1995; 15: 755–766.
41. Panush RS, Carter RL, Katz P, Kowsari B, Longley S, Finnie S. Diet therapy for rheumatoid arthritis. *Arthritis and Rheumatism* 1983;26:462-71.
42. Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal anti-inflammatory drugs. Clinical and immune correlates. *Arthritis and Rheumatism* 1995;38:1107-14.
43. Tedeschi SK, Costenbader KH. Is there a role for diet in the therapy of rheumatoid arthritis? *Current Rheumatology Reports* 2016;18:23.
44. Tedeschi, S. K., Frits, M., Cui, J., Zhang, Z. Z., Mahmoud, T., Iannaccone, C., Lin, T.-C., Yoshida, K., Weinblatt, M. E., Shadick, N. A. and Solomon, D. H. (2017), Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. *Arthritis Care & Research*. Accepted Author Manuscript. doi:10.1002/acr.23225
45. Hu Y, Costenbader KH, Gao X, et al. Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women. *The American Journal of Clinical Nutrition* 2014;100:959-67.
46. Esmailzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Dietary patterns and markers of systemic inflammation among Iranian women. *J Nutr*. 2007;137:992–8

47. Dalziel K, Segal L, de Lorgeril M. A mediterranean diet is cost-effective in patients with previous myocardial infarction. *J Nutr.* 2006;136:1879–85.
48. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. *J Am Coll Cardiol.* 2004;44:152–8.
49. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA.* 2004;292:1440–6.
50. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. *Ann Intern Med.* 2006;145:1–11.
51. Serrano-Martinez M, Palacios M, Martinez-Losa E, Lezaun R, Maravi C, Prado M, Martinez JA, Martinez-Gonzalez MA. A Mediterranean dietary style influences TNF-alpha and VCAM-1 coronary blood levels in unstable angina patients. *Eur J Nutr.* 2005;44:348–54.
52. Gao X, Bermudez OI, Tucker KL. Plasma C-reactive protein and homocysteine concentrations are related to frequent fruit and vegetable intake in Hispanic and non-Hispanic white elders. *J Nutr.* 2004;134:913–8.
53. Watzl B, Kulling SE, Moseneder J, Barth SW, Bub A. A 4-wk intervention with high intake of carotenoid-rich vegetables and fruit reduces plasma C-reactive protein in healthy, nonsmoking men. *Am J Clin Nutr.* 2005;82:1052–8.
54. Esmailzadeh A, Kimiagar M, Mehrabi Y, Azadbakht L, Hu FB, Willett WC. Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome. *Am J Clin Nutr.* 2006;84:1489–97.
55. Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F, Martin A, Andres-Lacueva C, Senin U, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. *J Clin Endocrinol Metab.* 2006;91:439–46.
56. Lopez-Garcia E, Schulze MB, Manson JE, Meigs JB, Albert CM, Rifai N, Willett WC, Hu FB. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. *J Nutr.* 2004;134:1806–11.
57. Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, Rosato R, Cassader M, Gentile L, et al. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. *Am J Clin Nutr.* 2006;84:1062–9.

58. King DE, Egan BM, Geesey ME. Relation of dietary fat and fiber to elevation of C-reactive protein. *Am J Cardiol*. 2003;92:1335–9. Erratum in: *Am J Cardiol* 2004;93:812.
59. Avellone G, Di Garbo V, Campisi D, De Simone R, Raneli G, Scaglione R, Licata G. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis. *Eur J Clin Nutr*. 2006;60:41–7.
60. Sierksma A, van der Gaag MS, Kluft C, Hendriks HFJ. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. *Eur J Clin Nutr*. 2002;56:1130–6.
61. van Herpen-Broekmans WM, Klopping-Ketelaars IA, Bots ML, Kluft C, Princen H, Hendriks HF, Tijburg LB, van Poppel G, Kardinaal AF. Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. *Eur J Epidemiol*. 2004;19:915–21.
62. Chien CT, Chang WT, Chen HW, Wang TD, Liou SY, Chen TJ, Chang YL, Lee YT, Hsu SM. Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis. *Arterioscler Thromb Vasc Biol*. 2004;24:1111–7.
63. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. *Cancer Res*. 2006;66:2483–7.
64. Erlinger TP, Guallar E, Miller ER III, Stolzenberg-Solomon R, Appel LJ. Relationship between systemic markers of inflammation and serum beta-carotene levels. *Arch Intern Med*. 2001;161:1903–8.
65. King DE, Mainous AG III, Geesey ME, Woolson RF. Dietary magnesium and C-reactive protein levels. *J Am Coll Nutr*. 2005;24:166–71.
66. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. *Am J Clin Nutr*. 2007;85:1068–74.